New Warnings Emerge for Estrogen Plus Progesterone

Two studies confirm major cardiovascular risks outweigh minor health benefits for postmenopausal women.

If you take hormone replacement therapy with estrogen plus progesterone (EP) to relieve the symptoms of menopause, you may want to consider switching to an alternative treatment. Thats because followup studies of two large, important clinical trials confirmed that EP actually increases the risk of coronary heart disease (CHD) for two years after it is taken, and only begins to offer some cardio protection after six years. Additionally, it increases the risk of breast cancer in postmenopausal women, and an increased risk of death from breast cancer and other causes persists after EP is discontinued.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access